Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics has announced the successful completion of Phase 1b clinical trials for their intravenous psilocin formulation, TRP-8803, with all 11 participants safely discharged. The trial aimed to optimize dosing for consistent psilocin blood levels, a crucial step towards future therapeutic applications in conditions such as Binge Eating Disorder and Fibromyalgia. The company anticipates patent filings based on these positive results, which also build on previous successful oral psilocybin trials.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.